Goldman Sachs downgraded GlaxoSmithKline (NYSE: GSK) from Neutral to Sell, saying the premium is unwarranted with sector-average growth.

The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE